ATE221886T1 - Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress - Google Patents
Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stressInfo
- Publication number
- ATE221886T1 ATE221886T1 AT98942330T AT98942330T ATE221886T1 AT E221886 T1 ATE221886 T1 AT E221886T1 AT 98942330 T AT98942330 T AT 98942330T AT 98942330 T AT98942330 T AT 98942330T AT E221886 T1 ATE221886 T1 AT E221886T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- stress
- treatment
- corticotropin releasing
- crh
- Prior art date
Links
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 title abstract 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 title abstract 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 title 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 title 2
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010048327 Supranuclear palsy Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000000112 colonic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5743297P | 1997-09-02 | 1997-09-02 | |
| PCT/US1998/018080 WO1999011643A1 (en) | 1997-09-02 | 1998-09-01 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE221886T1 true ATE221886T1 (de) | 2002-08-15 |
Family
ID=22010535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98942330T ATE221886T1 (de) | 1997-09-02 | 1998-09-01 | Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6245769B1 (de) |
| EP (1) | EP1012151B1 (de) |
| JP (1) | JP2001514260A (de) |
| CN (1) | CN1278819A (de) |
| AT (1) | ATE221886T1 (de) |
| AU (1) | AU9041198A (de) |
| BR (1) | BR9814458A (de) |
| CA (1) | CA2303280A1 (de) |
| DE (1) | DE69807085D1 (de) |
| IL (1) | IL134748A0 (de) |
| WO (1) | WO1999011643A1 (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6992188B1 (en) | 1995-12-08 | 2006-01-31 | Pfizer, Inc. | Substituted heterocyclic derivatives |
| ES2258479T3 (es) | 1999-10-01 | 2006-09-01 | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | Tecnica que permite calmar a las personas con la ayuda de composiciones de tratamientos personales. |
| WO2002006286A2 (en) * | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| US20020151527A1 (en) * | 2000-12-20 | 2002-10-17 | Benjamin Wiegand | Method for reducing acne or improving skin tone |
| BR0207297A (pt) | 2001-02-15 | 2005-04-19 | King Pharmaceuticals Inc | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| IL157615A0 (en) | 2001-03-13 | 2004-03-28 | Bristol Myers Squibb Co | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| CZ20033053A3 (en) * | 2001-05-14 | 2004-05-12 | Bristol@Myersásquibbápharmaácompany | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| US7462622B2 (en) | 2001-06-12 | 2008-12-09 | Glaxo Group Limited | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists |
| JP2004530722A (ja) * | 2001-06-29 | 2004-10-07 | アブ サイエンス | 骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法 |
| WO2003002108A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| JP2005500041A (ja) | 2001-06-29 | 2005-01-06 | アブ サイエンス | 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤 |
| US7678805B2 (en) | 2001-06-29 | 2010-03-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD) |
| CA2452371A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
| WO2003005969A2 (en) | 2001-07-12 | 2003-01-23 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
| US7276526B2 (en) | 2001-07-13 | 2007-10-02 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
| DK1433480T3 (da) * | 2001-07-13 | 2011-04-11 | Btg Internat Ltd Company | Lægemiddel indeholdende pyrimidin-derivat |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US20030119831A1 (en) | 2001-11-20 | 2003-06-26 | Hartz Richard A. | 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands |
| GB2384563A (en) * | 2002-01-29 | 2003-07-30 | Johnson & Johnson Consumer | Method of measuring the stress or relaxation level of a mammal |
| GB0203045D0 (en) * | 2002-02-08 | 2002-03-27 | Johnson & Johnson Consumer | Method of afefecting sleep and sleep-related behaviours |
| US20040175438A1 (en) * | 2003-03-03 | 2004-09-09 | Benjamin Wiegand | Methods for alleviating symptoms associated with menopause using sensory regimen |
| WO2005028480A2 (en) * | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| US20060128729A1 (en) * | 2004-11-23 | 2006-06-15 | Manojit Pal | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them |
| WO2006086464A2 (en) * | 2005-02-10 | 2006-08-17 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5ht modulators |
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| AU2006275694A1 (en) * | 2005-07-28 | 2007-02-08 | Bristol-Myers Squibb Company | Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists |
| US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
| US7851468B2 (en) * | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| ES2494365T3 (es) * | 2008-01-30 | 2014-09-15 | Genentech, Inc. | Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| SG171765A1 (en) | 2008-11-20 | 2011-07-28 | Genentech Inc | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
| JP5641664B2 (ja) | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用 |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| WO2011082267A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrazine compounds |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| AU2013283426B2 (en) | 2012-06-26 | 2018-02-22 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| WO2014009305A1 (en) | 2012-07-09 | 2014-01-16 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| SG11201505587YA (en) | 2013-01-23 | 2015-08-28 | Aldeyra Therapeutics Inc | Toxic aldehyde related diseases and treatment |
| UA116395C2 (uk) | 2013-09-06 | 2018-03-12 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ |
| AU2016220049C1 (en) | 2015-02-18 | 2021-02-25 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| AU2016311158A1 (en) | 2015-08-21 | 2018-04-05 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| CA3089159A1 (en) * | 2018-02-06 | 2019-08-15 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof |
| EP3833660A4 (de) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | Polymorphe verbindungen und verwendungen davon |
| JP7505786B2 (ja) | 2018-09-25 | 2024-06-25 | アルデイラ セラピューティクス， インコーポレイテッド | ドライアイ疾患を処置するための製剤 |
| JP7706758B2 (ja) | 2019-03-26 | 2025-07-14 | アルデイラ セラピューティクス， インコーポレイテッド | 眼科用製剤およびその使用 |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN112608316B (zh) * | 2019-07-30 | 2022-10-21 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类腺苷受体拮抗剂 |
| CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2643903A1 (fr) * | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| ATE139232T1 (de) * | 1989-10-11 | 1996-06-15 | Teijin Ltd | Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung |
| IT227968Y1 (it) | 1992-11-17 | 1998-01-21 | Moris Baroni | Ago per endovene e prelievi di forma estensibile, autoinglobante per evitare punture e contagi a persone e ambienti dopo l'uso |
| TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| JP3291299B2 (ja) * | 1994-06-06 | 2002-06-10 | ファイザー・インク | コルチコトロピン放出因子（ｃｒｆ）アンタゴニスト活性を有する置換ピラゾール |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| NZ284846A (en) * | 1994-06-16 | 1998-12-23 | Pfizer | 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| CA2223081C (en) | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
| ES2200039T3 (es) | 1995-12-08 | 2004-03-01 | Pfizer Inc. | Derivados heterociclicos sustituidos como antagonistas de crf. |
| US6140317A (en) * | 1996-01-23 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
-
1998
- 1998-09-01 AT AT98942330T patent/ATE221886T1/de not_active IP Right Cessation
- 1998-09-01 DE DE69807085T patent/DE69807085D1/de not_active Expired - Lifetime
- 1998-09-01 AU AU90411/98A patent/AU9041198A/en not_active Abandoned
- 1998-09-01 WO PCT/US1998/018080 patent/WO1999011643A1/en not_active Ceased
- 1998-09-01 IL IL13474898A patent/IL134748A0/xx unknown
- 1998-09-01 US US09/145,231 patent/US6245769B1/en not_active Expired - Lifetime
- 1998-09-01 EP EP98942330A patent/EP1012151B1/de not_active Expired - Lifetime
- 1998-09-01 CA CA002303280A patent/CA2303280A1/en not_active Abandoned
- 1998-09-01 CN CN98810908A patent/CN1278819A/zh active Pending
- 1998-09-01 JP JP2000508682A patent/JP2001514260A/ja active Pending
- 1998-09-01 BR BR9814458-8A patent/BR9814458A/pt not_active IP Right Cessation
-
2001
- 2001-02-21 US US09/789,673 patent/US6525056B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL134748A0 (en) | 2001-04-30 |
| US6245769B1 (en) | 2001-06-12 |
| EP1012151B1 (de) | 2002-08-07 |
| US20010025042A1 (en) | 2001-09-27 |
| DE69807085D1 (de) | 2002-09-12 |
| AU9041198A (en) | 1999-03-22 |
| US6525056B2 (en) | 2003-02-25 |
| BR9814458A (pt) | 2001-10-23 |
| CN1278819A (zh) | 2001-01-03 |
| CA2303280A1 (en) | 1999-03-11 |
| JP2001514260A (ja) | 2001-09-11 |
| EP1012151A1 (de) | 2000-06-28 |
| WO1999011643A1 (en) | 1999-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE221886T1 (de) | Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress | |
| MY132871A (en) | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | |
| LV12262A (lv) | Ar arilaminu kondenseti piridini un pirimidini | |
| BG108425A (en) | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor | |
| IL137019A0 (en) | Azolo triazines and pyrimidines | |
| DK0901374T3 (da) | Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser | |
| AU4270297A (en) | Pyrazinones and triazinones and their derivatives thereof | |
| ATE177101T1 (de) | Pyrrolopyrimidine als crf antagonisten | |
| ATE177099T1 (de) | Diazabicyclische neurokinin antagonisten | |
| MY146935A (en) | 4-(2-BUTYLAMINO-2, 7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-yl) PYRAZOLO-[1,5-a]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS | |
| MY141511A (en) | Azolo triazines and pyrimidines | |
| DE69210255D1 (de) | THIENOPYRAZIN-2,3-DIONE VERWENDBAR BEI DER BEHANDLUNG VON ZNS-STöRUNGEN, UND IHRE HERSTELLUNG. | |
| MY141752A (en) | Pyrazolotriazines as crf antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |